Zydelig® (idelalisib) – Indication withdrawals
On January 14, 2022, Gilead Sciences announced the voluntary withdrawal of the Zydelig (idelalisib) indications for the treatment of patients with relapsed follicular B-cell non-Hodgkin lymphoma (FL) who have received at least two prior systemic therapies and treatment of patients with relapsed small lymphocytic lymphoma (SLL) who have received at least two prior systemic therapies.
Top